  Psychiatric comorbidities are prevalent in patients with epilepsy and greatly contribute to the overall burden of disease. The availability of reliable biomarkers to diagnose epilepsy-associated comorbidities would allow for effective treatment and improved disease management. Due to their non-invasive nature , molecular imaging techniques such as positron emission tomography ( PET) are ideal tools to measure pathologic changes. In the current study we investigated the potential of (